ArticleJournal of pharmacology & pharmacotherapeutics
Expedited drug review process: Fast, but flawed.
Article in Journal of pharmacology & pharmacotherapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data.JRSM open · 2025Article
- Vaccine Innovation Meta-Model for Pandemic Contexts.Journal of pharmaceutical innovation · 2023Article
- Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.Pharmacy (Basel, Switzerland) · 2022Article
- The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.Journal of personalized medicine · 2021Article
- The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.Frontiers in pharmacology · 2019Review
- Pathways to ensure universal and affordable access to hepatitis C treatment.BMC medicine · 2018Article
- Recent advances in precision oncology research.NPJ precision oncology · 2018Article
- Striking balance between expedited review and expecting efficacious anticancer drug and biologics: An ongoing challenge.Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.